Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors.

Lovisa FalkmanAnders SundinBritt SkogseidJohan BotlingYvette BernardoGöran WallinLiang ZhangStaffan WelinIeva LaseKazhan MollazadeganJoakim Crona

Published in: Upsala journal of medical sciences (2024)

-mutated NEC is sensitive to treatment with BRAF- and MEK-inhibitor combination. These results further support that DNA sequencing should be considered as standard of care in NECs to screen for potential treatment targets.

Keyphrases

healthcare
palliative care
stem cells
high throughput
wild type
single cell
combination therapy
cell proliferation
cell free
bone marrow
cell therapy